Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eastern Bankshares Inc. Common Stock (EBC) vs 10X Genomics Inc (TXG) Price & Performance

Eastern Bankshares Inc. Common StockTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Eastern Bankshares Inc. Common Stock vs 10X Genomics Inc — how do they compare? Eastern Bankshares Inc. Common Stock trades at $20.77 (market cap $4.79B), while 10X Genomics Inc trades at $71.84 (market cap $9.35B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and Eastern Bankshares Inc. Common Stock pays a 2.67% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eastern Bankshares Inc. Common Stock for 0 Days and 10X Genomics Inc for 91 Days on average.

EBCTXG
Market Cap
$4.79B$9.35B
Volume
1,740,7164,039,449
Sector
FinancialsHealth
52-Week High
$23.65$97.74
52-Week Low
$16.73$11.83
Typical Hold Time
0 Days91 Days
Enterprise Value
$5.07B$8.88B
Dividend Yield
2.67%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eastern Bankshares Inc. Common Stock

Eastern Bankshares (EBC) trades at $20.96, down 0.85% on the day, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.71, net income margin of 33.47%, and recent Q2 2026 EPS beat. Analyst consensus is bullish with a $25.60 price target. Recent news highlights institutional buying and upcoming Q3 2026 earnings.

The outlook is positive given solid profitability, attractive valuation, and analyst support. Key risks include integration challenges from recent acquisitions and interest rate sensitivity. Upside potential exists if earnings momentum continues, but investors should monitor net cash flow trends and competitive pressures.

10X Genomics Inc

TXG trades at $73.10, down 2.78% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $642.82M in 2025 but a net loss of $43.54M, though recent quarters show earnings beats. Analyst consensus is mixed with a $83.30 price target. Positive news includes Atera shipments and a patent victory, but profitability remains a challenge.

The outlook hinges on Atera's commercial success driving future revenue growth and margin improvement. Risks include persistent losses, competitive pressures, and execution delays. Upside potential exists if new platforms gain traction, but investors should weigh high valuation multiples against ongoing unprofitability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EBC
100% Buy0% Sell
Avg holding period · 0 Days
TXG
17% Buy83% Sell
Avg holding period · 91 Days

Top news

Latest headlines on both assets

About Eastern Bankshares Inc. Common Stock

Eastern Bankshares, Inc. is the holding company for Eastern Bank, a Massachusetts-based bank operating more than 125 branches across eastern Massachusetts, southern and coastal New Hampshire, and Rhode Island, offering consumer and business banking along with wealth management through its Cambridge Trust divisions.

Read more on EBC →

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG →